B · Normal
[Merck's pembrolizumab triple-negative breast cancer indication expansion approved in China] On September 10, Merck announced that its PD-1 inhibitor Keytruda® (pembrolizumab) has been approved by the China National Medical Products Administration (NMPA) for the treatment of patients with early-stage high-risk triple-negative breast cancer (TNBC) in combination with neoadjuvant chemotherapy and pembrolizumab monotherapy after surgery.
medicine 🕐 2026-09-10 16:22
#medicine
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[Jiangsu: From January to August, the added value of industries above designated 09-22 11:22 [Novo Nordisk: Create a new business segment called blood and endocrine diseases 09-21 16:23 September 21st, Novo Nordisk stated that it plans to expand its production capac 09-21 16:06 September 21st, Novo Nordisk aims to have sales of product lines under developme 09-21 16:06 [Pharmaceutical sector’s rally expands Huaren Pharmaceutical and more than a doz 09-21 10:43 On September 18th, Anthropic established a biological laboratory for artificial 09-18 18:19

Comments

0/500
Captcha (click to refresh)
No comments yet